openPR Logo
Press release

Direct synthesis of novel antivirals

12-13-2006 06:24 PM CET | Health & Medicine

Press release from: PharmaInformatic

Model of deactivated HIV-protease, an essential enzyme of HIV

Model of deactivated HIV-protease, an essential enzyme of HIV

Endotherm and PharmaInformatic announce their cooperation in developing and optimising drugs against infectious diseases

12. December 2006 (Saarbruecken/Emden, Germany) - Endotherm and PharmaInformatic today announced a collaboration to develop and optimise novel antiviral agents. PharmaInformatic, a company specialising in cheminformatics, will use it´s expert systems to predict antiviral and pharmacokinetic properties of novel compounds based on computer calculations. Promising drug candidates will be identified and directly synthesised by Endotherm.

The average cost of developing a new medicine is about 900 million US dollars and the whole process can take more than 12 years. A large part of research costs are spent on compounds that never make it to market because of insufficient ADME/Tox-properties. ADME/Tox stands for absorption, distribution, metabolism, excretion and toxicity.

ADME/Tox-properties are determined years after synthesis of an agent in clinical trials. The prediction of compound properties allows selection of those compounds with the best ADME/Tox-properties to become useful drugs, whereby efficiency of drug research is considerably increased early in the drug development process.

PharmaInformatic
Dr. Wolfgang Boomgaarden
Friesenstr. 36
Tel: +49 (0)4921-99 33 60
26721 Emden
Germany
Contact: http://www.pharmainformatic.com/html/contact_us.html

Endotherm GmbH
The company was founded in 1999 and provides exclusive synthesis of medicinally relevant compounds for the discovery and development of small molecule drugs. Endotherm’s customers include many of the world leading pharmaceutical companies, like Altana, Aventis, Bayer, Boehringer Ingelheim, Merck, Solvay, Schwarz Bioscience, Schering and Takeda. Further information: www.endotherm.de

PharmaInformatic
The company develops expert systems to optimise drug discovery and development. PharmaInformatic´s platform technology contains millions of substances together with experimental data and thousands of 3D-models of biomolecules. Proprietary methods based on cheminformatics and bioinformatics allow the prediction of pharmaceutical activity and pharmacological properties of a substance. Further information: www.pharmainformatic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Direct synthesis of novel antivirals here

News-ID: 13679 • Views:

More Releases for Endotherm

Global Endotherm Knife Market Research scope, Methodology, Industry Chain Analys …
Introduction: An endotherm (from Greek “endon "within" and “ thermē "heat") is an organism that maintains its body at a metabolically favorable temperature, largely by the use of heat set free by its internal bodily functions instead of relying almost purely on ambient heat. A knife (plural knives) is a tool with a cutting edge or blade. The global market size of Endotherm Knife is $$ million in 2017 with $$
Global Endotherm Knife Market Research Report 2017
The Endotherm Knife Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Endotherm Knife industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Endotherm Knife market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well as manufacturing processes and